LNK mutations in JAK2 mutation-negative erythrocytosis

New England Journal of Medicine

Volumn 363, Issue 12, 2010, Pages 1189-1190

  Lasho, Terra L ^a   Pardanani, Animesh ^a   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; ERYTHROPOIETIN; JANUS KINASE 2; LNK PROTEIN; UNCLASSIFIED DRUG; LNK PROTEIN, HUMAN; PROTEIN; STOP CODON;

ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ERYTHROCYTOSIS; ERYTHROPOIESIS; GENE DELETION; GENE MUTATION; HUMAN; LETTER; MONOSOMY X; MYELOID METAPLASIA; NUCLEOTIDE SEQUENCE; PATHOGENESIS; POLYCYTHEMIA VERA; PRIORITY JOURNAL; THROMBOCYTHEMIA; CASE REPORT; GENETICS; MISSENSE MUTATION; PHENOTYPE; POLYCYTHEMIA; STOP CODON;

CODON, NONSENSE; DNA MUTATIONAL ANALYSIS; HUMANS; JANUS KINASE 2; MUTATION, MISSENSE; PHENOTYPE; POLYCYTHEMIA; PROTEINS;

EID: 77956670899     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1006966     Document Type: Letter

References (5)

1. Patnaik MM, Tefferi A. The complete evaluation of erythrocytosis: congenital and acquired. Leukemia 2009;23:834-44.
2. Pardanani A, Lasho TL, Finke C, Hanson CA, Tefferi A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia 2007;21:1960-3. (Pubitemid 47299970)
3. Gery S, Cao Q, Gueller S, Xing H, Tefferi A, Koeffler HP. Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F. J Leukoc Biol 2009;85:957-65.
4. Oh ST, Simonds EF, Jones C, et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 2010;116:988-92.
5. Gangat N, Tefferi A, Thanarajasingam G, et al. Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance. Eur J Haematol 2009;83:17-21.